XERIS BIOPHARMA HOLDINGS, INC. Revenue
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Revenue of $92.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $92.10M, a 28.74% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $83.13M, a 38.27% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $85.81M, a 42.78% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $74.38M, a 37.06% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $291.85M, a 43.72% increase from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $203.07M, a 23.89% increase from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $163.91M, a 48.68% increase from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $110.25M, a 122.32% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $92.10M 10-Q · filed 2026-08-06 | $175.23M 10-Q · filed 2026-08-06 | $261.03M derived: sum of 3 quarters · filed 2026-08-06 | $335.41M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $83.13M 10-Q · filed 2026-05-07 | $168.93M derived: sum of 2 quarters · filed 2026-05-07 | $243.31M derived: sum of 3 quarters · filed 2026-05-07 | $314.85M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $85.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $160.19M derived: sum of 2 quarters · filed 2026-03-02 | $231.73M derived: sum of 3 quarters · filed 2026-08-06 | $291.85M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $74.38M 10-Q · filed 2025-11-06 | $145.92M derived: sum of 2 quarters · filed 2026-08-06 | $206.04M 10-Q · filed 2025-11-06 | $266.14M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $71.54M 10-Q · filed 2026-08-06 | $131.66M 10-Q · filed 2026-08-06 | $191.76M derived: sum of 3 quarters · filed 2026-08-06 | $246.03M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $60.12M 10-Q · filed 2026-05-07 | $120.22M derived: sum of 2 quarters · filed 2026-05-07 | $174.49M derived: sum of 3 quarters · filed 2026-05-07 | $222.55M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $60.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $114.37M derived: sum of 2 quarters · filed 2026-03-02 | $162.43M derived: sum of 3 quarters · filed 2026-03-02 | $203.07M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $54.27M 10-Q · filed 2025-11-06 | $102.33M derived: sum of 2 quarters · filed 2025-11-06 | $142.97M 10-Q · filed 2025-11-06 | $187.36M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-06-30 | $48.06M 10-Q · filed 2025-08-07 | $88.70M 10-Q · filed 2025-08-07 | $133.09M derived: sum of 3 quarters · filed 2026-03-02 | $181.41M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-03-31 | $40.64M 10-Q · filed 2025-05-08 | $85.03M derived: sum of 2 quarters · filed 2026-03-02 | $133.35M derived: sum of 3 quarters · filed 2026-03-02 | $171.36M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2023-12-31 | $44.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $92.71M derived: sum of 2 quarters · filed 2026-03-02 | $130.72M derived: sum of 3 quarters · filed 2026-03-02 | $163.91M 10-K · filed 2026-03-02 | |||
| 2023-09-30 | $48.32M 10-Q · filed 2024-11-08 | $86.33M derived: sum of 2 quarters · filed 2024-11-08 | $119.52M 10-Q · filed 2024-11-08 | $152.67M derived: sum of 4 quarters · filed 2025-03-06 | |||
| 2023-06-30 | $38.01M 10-Q · filed 2024-08-08 | $71.20M 10-Q · filed 2024-08-08 | $104.35M derived: sum of 3 quarters · filed 2025-03-06 | $134.07M derived: sum of 4 quarters · filed 2025-03-06 | |||
| 2023-03-31 | $33.20M 10-Q · filed 2024-05-09 | $66.34M derived: sum of 2 quarters · filed 2025-03-06 | $96.06M derived: sum of 3 quarters · filed 2025-03-06 | $121.37M derived: sum of 4 quarters · filed 2025-03-06 | |||
| 2022-12-31 | $33.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $62.87M derived: sum of 2 quarters · filed 2025-03-06 | $88.17M derived: sum of 3 quarters · filed 2025-03-06 | $110.25M 10-K · filed 2025-03-06 | |||
| 2022-09-30 | $29.73M 10-Q · filed 2023-11-09 | $55.03M derived: sum of 2 quarters · filed 2023-11-09 | $77.10M 10-Q · filed 2023-11-09 | $98.53M derived: sum of 4 quarters · filed 2024-03-06 | |||
| 2022-06-30 | $25.31M 10-Q · filed 2023-08-08 | $47.38M 10-Q · filed 2023-08-08 | $68.81M derived: sum of 3 quarters · filed 2024-03-06 | $79.87M derived: sum of 4 quarters · filed 2024-03-06 | |||
| 2022-03-31 | $22.07M 10-Q · filed 2023-05-09 | $21.91M 10-Q · filed 2022-05-11 | $43.50M derived: sum of 2 quarters · filed 2024-03-06 | $54.56M derived: sum of 3 quarters · filed 2024-03-06 | $63.47M derived: sum of 4 quarters · filed 2024-03-06 | ||
| 2021-12-31 | $21.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $32.49M derived: sum of 2 quarters · filed 2024-03-06 | $41.40M derived: sum of 3 quarters · filed 2024-03-06 | $49.59M 10-K · filed 2024-03-06 | $49.28M 10-K · filed 2022-03-11 | ||
| 2021-09-30 | $11.06M 10-Q · filed 2022-11-09 | $11.04M 10-Q · filed 2021-11-10 | $19.97M derived: sum of 2 quarters · filed 2022-11-09 | $28.16M 10-Q · filed 2022-11-09 | $27.92M 10-Q · filed 2021-11-10 | $35.11M derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-06-30 | $8.91M 10-Q · filed 2022-08-10 | $17.10M 10-Q · filed 2022-08-10 | $24.05M derived: sum of 3 quarters · filed 2022-08-10 | $33.45M derived: sum of 4 quarters · filed 2022-08-10 | |||
| 2021-03-31 | $8.05M 10-Q · filed 2022-05-11 | $15.14M derived: sum of 2 quarters · filed 2022-05-11 | $24.54M derived: sum of 3 quarters · filed 2022-05-11 | ||||
| 2020-12-31 | $7.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $16.49M derived: sum of 2 quarters · filed 2022-03-11 | $20.16M 10-K · filed 2022-03-11 | ||||
| 2020-09-30 | $9.40M 10-Q · filed 2021-11-10 | $13.07M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |